Skip to main content
All lobbying filings

TODD STRATEGY GROUP

TODD STRATEGY GROUP filed a Q2 termination report for ALEXION PHARMACEUTICALS, INC. on October 14, 2025, reporting $80,000 in lobbying income.

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company.

All filings by TODD STRATEGY GROUP · Everything ALEXION PHARMACEUTICALS, INC. has reported

 Filing · LD-2 quarterly report Q2 termination
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Oct 14, 2025
Income
$80,000
What the client paid this registrant for the period.
Client based in
Massachusetts
Representation ended
Jun 30, 2025
The registrant reported terminating its work for this client.

Official filing document

 Lobbyists on this filing 6
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • DANIEL M TODD
    Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
  • ERIC BERGREN
    Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
  • KATHERINE FLEMING COTTON
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
  • TED LEHMAN
    Previously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
  • JEFF LUCAS
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Medicare/Medicaid

340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

Health Issues

General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem